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Background: A growing number of patients suffer from peripheral artery disease (PAD). Current therapies are often limited
by the extent of vascular pathology and the occurrence of restenosis after angioplasty. The stimulatory effect of growth factor
administration on collateral vessel formation (arteriogenesis) has evolved as a potential new treatment for this patient group.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was shown to stimulate arteriogenesis in small-animal models
and in a pilot study in patients with coronary artery disease. Although a recent clinical study demonstrated disappointing
results after subcutaneousGM-CSF application in patients with PAD,we hypothesized that intra-arterial cytokine application
using implantable infusion pumps might well stimulate arteriogenesis in a large-species model of peripheral vascular disease.
We also aimed to compare continuous and intermittent infusion regimens and to validate experimental and clinically available
measurements of collateral artery growth.
Methods: Twenty-four pigs underwent unilateral occlusion of the right femoral artery and received either GM-CSF continu-
ously, GM-CSF intermittently, or phosphate-buffered saline (PBS). After 1 week, collateral conductance was determined
under maximal vasodilatation with adenosine and by using a pump-driven extracorporal shunt system.
Results:Conductance showed a significant stimulatory effect ofGM-CSF on arteriogenesis (collateral conductance [mL/min/
mm Hg]: PBS, 37.7  5.4; GM-CSF continuous, 69.2  12.5; GM-CSF intermittent, 71.5  11.1). Flow measurements
under reactive hyperemia were consistent with these results (flow occluded/non-occluded hind limb: PBS, 40.5%  9.1%;
GM-CSF continuous, 48.9%3.9%;GM-CSF intermittent, 48.7%4.4%).Measurements of ankle/brachial indiceswere not
sensitive enough to detect the differences in collateral growth between the three groups.
Conclusion: These results demonstrate the proarteriogenic properties of GM-CSF in larger animal species, revealing compa-
rable efficacy of continuous and intermittent intra-arterial infusion. Furthermore,we provide evidence that implantable pumps
offer a possible means for the intra-arterial application of growth factors. Intra-arterial application of GM-CSF might be a
future treatment option for vascular occlusive disease. Finally, we show that in the peripheral circulation, pressure measure-
ments alone have a low sensitivity to determine the effects of proarteriogenic therapy compared with flow or combined
flow-pressure measurements. (J Vasc Surg 2006;43:1263-69.)
Clinical Relevance: The stimulation of collateral artery growth (arteriogenesis) with granulocyte-macrophage colony-
stimulating factor (GM-CSF) has evolved as a promising treatment strategy for patients with coronary artery disease, but a
recent study in patients with peripheral artery disease showed negative results after subcutaneous GM-CSF therapy.
The current experimental study in a porcine peripheral artery disease model now elucidates the efficacy of continuous
intra-arterial GM-CSF application in a large-animal model of peripheral artery disease. A programmable pump-system was
implemented that might overcome the delivery problem that was encountered during the patient trial. Clinical and
experimental end points were applied to compare a continuous with an intermittent treatment regimen.From the Department of Cardiology and Angiology, University Hospital
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doi:10.1016/j.jvs.2006.02.049Peripheral artery disease (PAD) is estimated to symp-
tomatically affect 3% to 6% of men aged60 years. Despite
the progress in diagnosis and prevention, roughly 25% of all
patients with intermittent claudication have significant dis-
ease progression, many to the point of developing critical
limb ischemia.1 Current interventional treatment options
include endovascular or surgical revascularization; how-
ever, not all atherosclerotic occlusions can be revascularized
by these approaches. Furthermore, many PAD patients
have an increased operative risk.
The pharmacologic stimulation of true collateral artery
growth (arteriogenesis) is a promising alternative therapeu-
tic modality.2 In contrast to angiogenesis, which describes
the formation of capillary networks through endothelial
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ies from small pre-existing anastomoses.3 One promising
candidate for therapeutic stimulation of arteriogenesis is
granulocyte-macrophage colony-stimulating factor (GM-
CSF), which was shown to promote collateral artery growth
by prolongation of monocyte survival in a rabbit hindlimb
model of arteriogenesis.4
In a clinical pilot trial, GM-CSF increased collateral
flow in patients with coronary artery disease,5 whereas in
the recently conducted START trial, no significant effects
were seen in PAD patients.6 In contrast to the experimental
study and the coronary artery disease trial, in the Stimula-
tion of Arteriogenesis (START) trial GM-CSF, was applied
solely via a subcutaneous route, which might well be an
explanation for the negative outcome of the study.
We hypothesized that arteriogenesis can be stimulated
by GM-CSF application in a large-animal model of PAD if
the cytokine is infused locally into the collateral circulation
over a prolonged time period. The substance was applied
via clinically available programmable implantable infusion
pumps. Because GM-CSF has previously been shown to
downregulate the expression of its own receptor (GM-
CSFR) on circulating cells and thereby decrease the effi-
cacy of the compound in a tachyphylactic reaction,7 we also
compared a continuous with an intermittent intra-arterial
treatment regimen. To measure efficacy, we applied the
clinically applicable end points of ankle/brachial-index
(ABI) and flow under reactive hyperemia, as well as the
experimental end point of collateral conductance.
MATERIAL AND METHODS
Operational procedure. The current study was per-
formed in conformity with theGuide for the Care andUse of
Laboratory Animals published by the USNational Institute
of Health (NIH Publication No. 85-23, revised 1996),
after appropriate institutional approvals were secured.
Twenty-four German Landrace pigs with a mean body
weight of 75  3 kg received an intramuscular injection
of flunitrazepam (0.2 mg/kg body weight) and 10 to 20
mg/kg of ketamine. Anesthesia was intravenously induced
with 0.001mg/kg of fentanyl and 2 to 4 mg/kg of propo-
fol. After muscular relaxation had been induced with 0.08
mg/kg of vecuronium, the animals were ventilated with
N2O:O2 in a ratio of 2:1. Anesthesia was maintained by
continuous intravenous infusion of 0.06 mg/kg/h of ve-
curonium, 0.001 mg/kg/h of fentanyl, and 5 mg/kg/h of
propofol.
Femoral artery ligation. All animals underwent uni-
lateral occlusion of the right femoral artery, 3 cm distal
from the branching of the circumflex femoral artery. The
circumflex femoral artery was also ligated to further reduce
blood flow to the distal hindlimb. A sterile catheter was
inserted and fixed upstream in the proximal stump of the
occluded femoral artery, ensuring delivery of the substances
directly into the collateral circulation. The catheter was
tunneled subcutaneously and connected to an electronic
pump device (Synchromed EL, Medtronic, Inc, Minn),which was implanted in the subcutaneous tissue of the
lower abdomen.
Observation period. During the observation period,
the animals were allowed to move freely, with access to
water and chow. Eight animals received human recombi-
nant GM-CSF (Sargramostin, Berlex, Inc, Montville, NJ)
in a 0.05% solution of phosphate-buffered saline (PBS) via
the implantable pump device at a pump rate of 750 L/d
continuously over the whole observation period of 7 days.
Another group of eight animals received GM-CSF in an
intermittent fashion (1-hour infusion, 7-hour break, three
cycles per day). Both groups received a total of 5 g/kg
GM-CSF per day intra-arterially in correspondence with
the clinical trials that used subcutaneous injections for
proarteriogenic therapy and with the clinically used doses
for stem cell mobilization. The third group received PBS
only via continuous infusion.
Hemodynamic measurements. With some adapta-
tions, measurements were performed as previously de-
scribed.8 Animals were anesthetized and heparinized. For
the ABI index measurements, the right radial artery was
dissected and cannulated for continuous pressure monitor-
ing. The abdomen was incised along the median and the
peritoneum was opened. Afterwards, the abdominal aorta
was carefully dissected from the iliac bifurcation to the
branching of the renal arteries. The caudal mesenteric
artery was dissected and cannulated for monitoring and
measurement of the prestenotic blood pressure during the
collateral conductance measurements. Two ultrasound flow-
probes (Transonic Systems, Inc, Ithaca, NY) were placed
around the common iliac arteries, one on each side. For the
monitoring and measurements of the poststenotic blood
pressures, the very distal posterior tibial arteries were dis-
sected and cannulated with a sterile polyethylene catheter.
For all hemodynamic measurements, the catheters of the
mesenteric artery, the radial artery, and both posterior tibial
arteries were connected to pressure transducers.
ABI and iliac artery flow at rest and during reactive
hyperemia. The ratio of posterior tibial artery pressure and
radial artery pressure served as the ABI. For the induction
of reactive hyperemia, the abdominal aorta was clamped for
1 minute between the mesenteric and renal arteries. After
the clamp was released, maximal iliac blood flow and ac-
companying blood pressure were measured. The mean of
three measurements (with a minimum of 5 minutes be-
tween each measurement) was used for data analysis.
Maximal iliac artery flow after clamp release was ex-
pressed as a ratio of occluded/nonoccluded hindlimb. In
addition wemeasured flow/pressure-deficit ratio (FPDR
iliac artery flow/p) as previously described.9 FPDR cor-
responds to the collateral conductance, but whereas true
conductance is derived from the slope of the curve of
several flow/pressure relations using an extracorporal cir-
culation, FPDR is derived from a single measurement un-
der reactive hyperemia. FPDR of the ligated hindlimb is
expressed as an absolute value in mL/min/mmHg, as well
as the ratio of the occluded vs nonoccluded hindlimb to
correct for differences in systemic pressure.
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pleting the reactive hyperemia measurements, an extracor-
poral circulation was created to allow assessment of collat-
eral conductance in a standardized manner. The abdominal
aorta was cannulated with the tip of the catheter pointing
upstream and another catheter was inserted with the tip
pointing downstream. The tip of the distal catheter was
placed 2 cm proximal to the branching of the caudal
mesenteric artery. This shunt system was driven by a roller-
pump, and a bubble trap/arterial filter was inserted into the
shunt system to prevent arterial embolism. This setup al-
lows the installment of different perfusion levels (Fig 1).
Both hindlimbs were then perfused at different pressure/
flow levels under complete vasodilatation via continuous
infusion of adenosine (1 mg/kg/min). At each pressure/
flow level, blood pressure in the caudal mesenteric artery
(prestenotic pressure) and the posterior tibial arteries (post-
stenotic pressure), as well as flow in the common iliac
artery, was measured continuously.
For each level of perfusion pressure, the pressure gra-
dient (p  ppre-stenotic  ppoststenotic) was plotted against
the corresponding blood flow in the common iliac artery
(mL/min). Collateral conductance was then calculated
from the slope of the resulting curve and expressed as
mL/min/mmHg. Collateral conductance is the reciprocal
value of the vascular resistance of the collateral arterial
network and the most accurate measurement to express the
capacity of a collateral network.10 In the pig hindlimb,
conductance of the unrecruited collateral circulation has
previously been shown to be relatively independent of
interindividual variation in animals of the same size and
weight.11
Statistical analysis. All results are expressed as mean
standard deviation. Intergroup comparisons were performed
using a one-way analysis of variance and the Bonferroni cor-
rection. Values of P .05 were considered to be statistically
peripheral pressure
peripheral pressureroller pump
Aorta
perfusion pressure
flow probes
deep femoral artery
recruited
collateral
arteries
double ligaton
pre-existing
anastomoses
adenosine
Fig 1. Experimental setup for assessment of collateral conduc-
tance. The establishment of an extra-corporal circulation allows
measurements under maximum vasodilatation and at different
flow/pressure levels.significant.RESULTS
No animal died during or after the initial operation or
had loss of hindlimb function, necrosis, or gangrene. Post-
operatively, all animals appeared clinically healthy and
showed normal behavior regarding food and water uptake.
There was no significant difference in body weight between
the treatment groups at baseline or after the treatment
period. The implantation of the programmable electronic
pumps did not impair the animals or lead to infection. One
week after femoral artery occlusion and pump implanta-
tion, hemodynamic parameters were assessed (Table I
and II.)
ABI and iliac artery flow at rest and during reactive
hyperemia. At resting conditions, no statistically signifi-
cant difference in the ABI between control and treated
groups was found (n  8 for each group). Although ABI
decreased strongly in all groups during reactive hyperemia
after temporary clamping of the aorta, this decrease did not
differ significantly between the groups (Fig 2). Resting flow
also did not differ between groups (data not shown). Dur-
ing reactive hyperemia, a significantly increased iliac artery
flow and an increase in FPDRwere observed in both groups
of GM-CSF treated animals compared with control animals
(Fig 3).
Collateral conductance measurements. Collateral con-
ductance measurements under pump-controlled pressure
and flow conditions during extracorporal circulation con-
firmed the stimulatory effect of GM-CSF (Fig 4). No
significant difference was observed for any of the above-
mentioned parameters between continuous and intermit-
tent infusion of GM-CSF.
DISCUSSION
We report that the proarteriogenic properties of GM-
CSF are preserved in a large animal species when applied
intra-arterially. Furthermore, we suggest the applicability
of clinically available infusion pumps as a platform for the
intra-arterial delivery of growth factors. Intermittent intra-
arterial application did not further increase efficacy. Finally,
Table I. Collateral conductance of the occluded
hindlimb 7 days after femoral artery occlusion (raw data)*
Animal PBS
GM-CSF
continuous
GM-CSF
intermittent
1 47.1 65.6 69.4
2 38.7 76.3 64.1
3 29.2 47.7 87.5
4 35.4 67.7 84.1
5 40.8 79.2 63.6
6 41.0 59.8 76.1
7 34.4 88.4 54.2
8 35.2 68.7 72.9
Mean  SD 37.7  5.4 69.2  12.5 71.5  11.1
PBS, Phosphate buffered saline; GM-CSF, granulocyte-macrophage colony-
stimulating factor.
*Units: mL/min/mm Hg.we show that combined flow/pressure measurements are
JOURNAL OF VASCULAR SURGERY
June 20061266 Grundmann et almore sensitive to detect stimulation of arteriogenesis than
pressure measurements alone.
Numerous experimental techniques have been devel-
oped to assess the effects of arteriogenesis on tissue perfu-
sion. Experimental models in small animals are useful to
study molecular aspects of arteriogenesis, for example, in
genetic knockouts, but may not be sufficient to predict the
time course of the arteriogenic response of collateral arter-
ies in larger species. Therefore, these small-animal models
may not accurately reflect the process of arteriogenesis in
human subjects. Because collateral vessels in mice require
only a few cell cycles of smooth muscle and endothelial cell
proliferation to reach their final effective diameter, collateral
arterioles in larger-sized animals such as the pig closely ap-
proximate the growth dynamics to be expected in humans.
Because of the larger size of the pig compared with the
previous animal models, the pig hindlimb model provides a
Table II. Hemodynamic results 7 days after femoral arter
PBS
ABI at rest 0.70  0.05
ABI during hyperemia 0.28  0.03
Flow right vs left (%) 40.5  9.1
FPDR occluded limb† 23.3  2.8
FPDR right vs left (%) 14.9  3.4
Conductance† 37.7  5.4
PBS, Phosphate buffered saline; GM-CSF, granulocyte-macrophage colo
flow/pressure-deficit ratio.
*For both GM-CSF groups vs PBS.
†Units: mL/min/mm Hg.
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Fig 2. Ankle/brachial index (ABI). Assessment of ABI as a clin-
ically available parameter of collateralization at rest as well as
during reactive hyperemia failed to detect significant differences
between the treatment groups. Data shown are mean  standard
deviation. PBS, Phosphate-buffered saline; GM-CSF, granulocyte-
macrophage colony-stimulating factor.y occlusion
GM-CSF
continuous
GM-CSF
intermittent P
0.70  0.03 0.69  0.07 NS
0.30  0.07 0.29  0.08 NS
48.9  3.9 48.7  4.4 0.05*
28.6  3.0 29.6  5.0 0.05*
19.1  1.4 18.8  1.4 0.05*
69.2  12.5 71.5  11.1 0.05*
ny-stimulating factor; ABI, ankle/brachial index; NS, not significant; FPDR,broad spectrum of functional hemodynamic parameters0
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Fig 3. Hemodynamic assessment of iliac artery flow and flow/
pressure-deficit ratio (FPDR) as a relative value of occluded/
nonoccluded hindlimb during reactive hyperemia. Measure-
ment of (A) iliac artery flow and (B) FPDR after temporary
occlusion of the abdominal aorta showed a significant increase
in iliac artery flow during reactive hyperemia in the granulocyte-
macrophage colony-stimulating factor (GM-CSF) treated
groups. Data shown are mean  standard deviation. PBS,
Phosphate-buffered saline.
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conditions of maximal vasodilatation. We chose a 1-week
observation period because the natural time course of arte-
riogenesis in the otherwise healthy animals tends to mask
stimulatory treatment effects at long time points.12
In this study we evaluated the effect of GM-CSF to
enhance arteriogenesis. Previous studies have shown that
the intra-arterial application of GM-CSF into the collateral
circulation of the rabbit hindlimb leads to a significant
increase in collateral conductance. Although the mecha-
nisms by which GM-CSF enhances arteriogenesis remain
partially unclear, increased survival of infiltrating mono-
cytes via inhibition of apoptosis seems to play a role.4
Infiltratingmonocytes are important mediators of collateral
artery growth,13 accumulating around proliferating blood
vessels and contributing to the arterial remodeling process
via expression of matrix metalloproteinases, growth factors,
and cytokines with known involvement in arteriogenesis
such as tumor necrosis factor-,14 transforming growth
factor-	, fibroblast growth factor-2, and GM-CSF itself.
However, after transmigration into the perivascular tissue,
the life span of macrophages is relatively short and depends
on specific growth factors.15
Walsh and Sata16,17 propose that apoptosis might be
already initiated during transendothelial migration via Fas-
ligand-receptor binding. This might be counteracted by
GM-CSF application and therefore prolong monocyte/
macrophage survival. Another potential mechanism of ac-
tion might be the release of pluripotent cell populations
from the bone marrow, which might act as stimulators of
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Fig 4. Collateral conductance measurements under complete
and maximal vasodilatation achieved by continuous adenosine
infusion and extra-corporal circulation. Collateral conductance
(mL/min/mm Hg) as a parameter of flow-increase per increase in
blood pressure gradient was significantly higher in the granulocyte-
macrophage colony-stimulating factor (GM-CSF) treated groups,
although there was no significant difference between continuous
and intermittent drug application. Data shown are mean  stan-
dard deviation. PBS, Phosphate-buffered saline.collateral artery growth.18Granulocyte-colony stimulating factor (G-CSF) is an-
other growth factor acting on the myeloid lineage that has
recently been found to improve myocardial perfusion in
combination with the intracoronary delivery of progenitor
cells.19 G-CSF has fewer side effects compared with GM-
CSF and is therefore probably more easily implemented in
clinical trials. However, no data are available yet on the
specific effects of G-CSF on arteriogenesis.
The mode of administration is an important issue in the
development of clinically feasible proarteriogenic therapies.
In our previously mentioned rabbit hindlimb model, we
applied GM-CSF intra-arterially, directly into the collateral
circulation.4 Seiler et al5 showed in a small pilot study in 20
patients with coronary heart disease that GM-CSF treat-
ment also induces an increase of collateral flow in humans.5
In this study, GM-CSFwas given as an intra-coronary bolus
followed by long-term subcutaneous application.
In the recently published START trial, GM-CSF was
applied solely subcutaneously in 40 patients with PAD.6,20
This was done because intra-arterial application was thought
to be too cumbersome in the setting of PAD.No significant
difference was detected in this study between the control
and the treatment group for our primary end point walking
distance. It can be postulated that the mode of application
negatively influenced the outcome of the START study.
The present study for the first time proves the proarte-
riogenic capacity of GM-CSF in a large-animal model of
PAD, showing almost a doubling of collateral conductance
in treated animals compared with control animals. We do
realize that this by no means guarantees the success of the
eventual intra-arterial application of GM-CSF in PAD pa-
tients (vs the subcutaneous application in the START-
study). It is an encouraging result though, especially taking
into account the positive outcome previously reported for
patients with coronary artery disease, and it justifies further
studies on intra-arterial application of proarteriogenic fac-
tors in PAD patients.
Because it was previously shown that GM-CSF expo-
sure may downregulate the expression of its own receptor
on circulating monocytes and progenitor cells,7 we also
compared an intermittent infusion with continuous infu-
sion. Intermittent infusion did not further enhance the
pro-arteriogenic efficacy of GM-CSF. Thus, the present
study does not support the use of intermittent infusion of
GM-CSF. It can be envisioned though that intermittent
dosage regimens are beneficial when different growth fac-
tors (several growth factors are known to down regulate
their own receptors) are used, or even more interestingly,
when combination therapies are used.
CONCLUSIONS
The present study demonstrates the applicability of
programmable and implantable perfusion pumps for such
dosage regimens. It should be noted that these pump are
designed for long-term subcutaneous implantation and can
be reprogrammed and refilled if needed.
We used an acute ligation of the femoral artery in our
model, whereas PAD-patients have a chronic, progressive
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albeit mostly insufficiently, recruited. A local and continu-
ous administration as can be achieved with implantable
pumps might be a prerequisite to induce arteriogenesis in
these patients.
Recent clinical studies have raised safety concerns for
the application of both GM-CSF and G-CSF for the stim-
ulation of neovascularization. Patients receiving a high dose
of growth factor appear to be at a higher risk of acute
coronary events than the control group. Therefore, it has
been advised that future trials of growth factor therapy for
the stimulation vascular proliferation should be limited to
patients with no other therapeutic option until the safety of
these drugs is further investigated.21
Finally, the present study confirms the feasibility of
combined flow/pressure measurements to assess the effi-
cacy of collateral artery growth. Because of the strong
dependency of flow on the diameter of the blood vessel,
conventional imaging techniques such as angiographic
scoring are not sensitive enough to detect the small differ-
ences in vascular anatomy that might result in significant
functional improvement.22 Although an improvement of
patient symptoms such as pain and walking distance is the
final aim of clinical studies to stimulate arteriogenesis, these
parameters are subjective, and additional end points are
needed. Under experimental conditions, an assessment of
perfusion-dependent muscle function, as performed by Lee
et al,23 is more accurate. The invasive instrumentation at
the site of collateral growth, however, makes such an assess-
ment of muscle function difficult for arteriogenesis studies.
In our own study, iliac flow and the FPDR under
reactive hyperemia was increased in GM-CSF treated ani-
mals compared with controls. This is important informa-
tion for future clinical trials, because the measurement of
true collateral conductance, as described in this study, will
never be feasible in the clinical setting, whereas ABI, iliac
flow, and the FPDR20 can be obtained relatively easily in
patients. ABI at rest and under reactive hyperemia did not
differentiate between groups, whereas measurements of
collateral conductance revealed a difference of almost 100%
between treated and untreated animals. This stresses the
need for combined pressure-flow measurements also in the
clinical setting of peripheral artery disease.
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